Windlas Biotech's Stock Price Soars by 12.06% on Strong Market Performance
Windlas Biotech, a smallcap pharmaceutical company, has seen a 12.06% increase in its stock price on November 6, 2024. This is due to the company's strong performance in the market, with its stock reaching a new 52-week and all-time high of Rs. 1197. Windlas Biotech has also outperformed its sector and the Sensex, showcasing its potential for growth in the pharmaceutical industry.
Windlas Biotech, a smallcap pharmaceutical company, has seen a significant increase in its stock price by 12.06% on November 6, 2024. This rise in stock price has been attributed to the company's strong performance in the market.
According to MarketsMOJO, a leading stock market analysis platform, Windlas Biotech's stock call is currently 'Hold'. The company's stock has reached a new 52-week and all-time high of Rs. 1197 on the same day. This is a significant achievement for the company and shows its potential for growth in the market.
In today's trading, Windlas Biotech has outperformed the sector by 11.67%, showcasing its strong performance in comparison to its competitors. The stock has also been gaining for the last two days, with a rise of 13.96% in this period. It reached an intraday high of Rs. 1197, which is a 14.17% increase from its previous closing price.
The stock has shown high volatility today, with an intraday volatility of 8.3%. This is calculated from the weighted average price, indicating the fluctuation in the stock's price throughout the day. Despite this, Windlas Biotech is trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which is a positive sign for the company.
In comparison to the Sensex performance, Windlas Biotech has outperformed with a 1-day performance of 11.87% while the Sensex has only seen a 0.73% increase. In the last month, Windlas Biotech has also outperformed the Sensex with a 33.41% increase, while the Sensex has seen a -2.00% decrease.
Overall, Windlas Biotech's stock has shown strong performance in the market, with a significant increase in its stock price and outperforming its competitors and the Sensex. This showcases the company's potential for growth and its strong position in the pharmaceutical industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
